Arch Therapeutics OTC Stock Top Insiders
| ARTH Stock | USD 1.18 0.04 3.51% |
Arch Therapeutics employs about 8 people. The company is managed by 11 executives with a total tenure of roughly 42 years, averaging almost 3.0 years of service per executive, having 0.73 employees per reported executive. Assessment of Arch Therapeutics' management performance can provide insight into the firm performance.
| Terrence Norchi CEO President CEO, Director |
| Avtar Dhillon Chairman Chairman of the Board |
Arch |
Arch Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (1.1363) % which means that it has lost $1.1363 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (40.148) %, meaning that it created substantial loss on money invested by shareholders. Arch Therapeutics' management efficiency ratios could be used to measure how well Arch Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Arch Therapeutics Workforce Comparison
Arch Therapeutics is rated third in number of employees category among related companies. The total workforce of Health Care industry is presently estimated at about 79.0. Arch Therapeutics retains roughly 8.0 in number of employees claiming about 10% of equities under Health Care industry.
Arch Therapeutics Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Arch Therapeutics Price Series Summation is a cross summation of Arch Therapeutics price series and its benchmark/peer.
Arch Therapeutics Notable Stakeholders
An Arch Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Arch Therapeutics often face trade-offs trying to please all of them. Arch Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Arch Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Terrence Norchi | President CEO, Director | Profile | |
| Avtar Dhillon | Chairman of the Board | Profile | |
| Richard Davis | CFO and Treasurer | Profile | |
| Punit Dhillon | Independent Director | Profile | |
| James Sulat | Independent Director | Profile | |
| Michael Abrams | Chief Officer | Profile | |
| Daniel Yrigoyen | VP Sales | Profile | |
| Terrence MD | Chairman, CoFounder | Profile | |
| Daniel Wadsworth | Advisor Commercialization | Profile | |
| Steven Kates | VP Technology | Profile | |
| Rutledge EllisBehnke | CoFounder Advisor | Profile |
About Arch Therapeutics Management Performance
The success or failure of an entity such as Arch Therapeutics often depends on how effective the management is. Arch Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Arch management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Arch management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. The company was founded in 2006 and is based in Framingham, Massachusetts. Arch Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 10 people.
The data published in Arch Therapeutics' official financial statements usually reflect Arch Therapeutics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Arch Therapeutics. For example, before you start analyzing numbers published by Arch accountants, it's critical to develop an understanding of what Arch Therapeutics' liquidity, profitability, and earnings quality are in the context of the Health Care Equipment & Supplies space in which it operates.
Please note, the presentation of Arch Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Arch Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Arch Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Arch Therapeutics. Please utilize our Beneish M Score to check the likelihood of Arch Therapeutics' management manipulating its earnings.
Arch Therapeutics Workforce Analysis
Traditionally, organizations such as Arch Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Arch Therapeutics within its industry.Arch Therapeutics Manpower Efficiency
Return on Arch Therapeutics Manpower
| Revenue Per Employee | 2K | |
| Revenue Per Executive | 1.4K | |
| Net Loss Per Employee | 659.5K | |
| Net Loss Per Executive | 479.6K | |
| Working Capital Per Employee | 1.9K | |
| Working Capital Per Executive | 1.4K |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arch Therapeutics. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Complementary Tools for Arch OTC Stock analysis
When running Arch Therapeutics' price analysis, check to measure Arch Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arch Therapeutics is operating at the current time. Most of Arch Therapeutics' value examination focuses on studying past and present price action to predict the probability of Arch Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arch Therapeutics' price. Additionally, you may evaluate how the addition of Arch Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |